News & Updates

Findings from the phase III NCRI* FLAIR** trial demonstrate the benefit of MRD***-guided ibrutinib + venetoclax (I+V) in chronic lymphocytic leukaemia (CLL) patients with gene aberrations compared with ibrutinib and fludarabine, cyclophosphamide, and rituximab (FCR).

Treatment with zongertinib in Asian patients with advanced HER2-mutant nonsmall cell lung cancer (NSCLC), who have received prior systemic therapy, delivers robust efficacy and elicits an acceptable safety profile, consistent with the overall global analysis, reports a China study.

The use of single tremelimumab (T) regular interval durvalumab (D), or STRIDE, results in a manageable safety profile in Asian patients with unresectable hepatocellular carcinoma (uHCC), as shown by the preliminary results of the SIERRA study.